Skip to main content

Advertisement

Fig. 1 | Cancer Communications

Fig. 1

From: Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Fig. 1

Functional assessment of cancer therapy (FACT)-General for the quality of life of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in the eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) arms. a Overall scores; b physical well-being (PWB) scores; c social well-being (SWB) scores; d emotional well-being (EWB) scores; e functional well-being (FWB) scores. All data are presented as mean values, with bars indicate standard deviation

Back to article page